Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPD

European Respiratory Journal

Volumn 22, Issue 6, 2003, Pages 926-930

  Zuhlke I E ^a   Kanniess, F ^a   Richter, K ^a   Nielsen Gode, D ^a   Bohme S ^a   Jorres R A ^a   Magnussen, H ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

Airway obstruction; Airway protection; Antileukotrienes; Corticosteroids; Recovery time; Salbutamol

Indexed keywords

CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; SALBUTAMOL; SODIUM CHLORIDE;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; BODY PLETHYSMOGRAPHY; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; MALE; METERED DOSE INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VERTIGO;

EID: 0348013231     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00046203     Document Type: Article

References (30)

1. Schoeffel RE, Anderson SD, Altounyan RE. Bronchial hyperreactivity in response to inhalation of ultrasonic nebulised solutions of distilled water and saline. Br Med J 1981; 283: 1285-1287.
2. Kips JC, Peleman RA, Pauwels RA. Methods of examining induced sputum: do differences matter? Eur Respir J 1998; 11: 529-533.
3. Richter K, Holz O, Jörres RA, Mücke M, Magnussen H. Sequentially induced sputum in patients with asthma or chronic obstructive pulmonary disease. Eur Respir J 1999; 14: 697-701.
4. Rytilä PH, Lindqvist AE, Laitinen LA. Safety of sputum induction in chronic obstructive pulmonary disease. Eur Respir J 2000; 15: 1116-1119.
5. Taube C, Holz O, Mücke M, Jörres RA, Magnussen H. Airway response to inhaled hypertonic saline in patients with moderate to severe COPD. Am J Respir Crit Care Med 2001; 164: 1810-1815.
6. Holz O, Kips J, Magnussen H. Update on sputum methodology. Eur Respir J 2000; 16: 355-359.
7. Rodwell LT, Anderson SD, Seale JP. Inhaled clemastine inhibits airway narrowing caused by aerosols of non-isotonic saline. Eur Respir J 1991; 4: 1126-1134.
8. Finnerty JP, Wilmont C, Holgate ST. Inhibition of hypertonic saline-induced bronchoconstriction by terfenadine and flurbiprofen: evidence for the predominant role of histamine. Am Rev Respir Dis 1989; 140: 593-597.
9. Makker HK, Holgate ST. The contribution of neurogenic reflexes to hypertonic saline-induced bronchoconstriction in asthma. J Allergy Clin Immunol 1993; 92: 82-88.
10. Kelly MM, Keating V, Leigh R, et al. Analysis of fluid phase mediators. Eur Respir J 2002; 20: 24-39.
11. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: 77-121.
12. Holz O, Jörres RA, Koschyk S, Speckin P, Welker L, Magnussen H. Changes in sputum composition during sputum induction in healthy and asthmatic subjects. Clin Exp Allergy 1998; 28: 284-292.
13. Taube C, Lehnigk B, Paasch K, Kirsten DK, Jörres RA, Magnussen H. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 216-220.
14. Pesci A, Rossi GA, Bertorelli G, Aufiero A, Zanon P, Olivieri D. Mast cells in the airway lumen and bronchial mucosa of patients with chronic bronchitis. Am J Respir Crit Care Med 1994; 149: 1311-1316.
15. Lamb D, Lumsden A. Intra-epithelial mast cells in human airway epithelium: evidence for smoking-induced changes in their frequency. Thorax 1982; 37: 334-342.
16. Grashoff WF, Sont JK, Sterk PJ, et al. Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages. Am J Pathol 1997; 151: 1785-1790.
17. Turnbull LW, Turnbull LS, Crofton J, Kay AB. Variations in chemical mediators of hypersensitivity in the sputum of chronic bronchitis: correlation with peak expiratory flow. Lancet 1978; 2: 184-186.
18. Rutgers SR, Koëter GH, van der Mark TW, Postma DS. Protective effect of oral terfenadine and not inhaled ipratropium on adenosine 5′-monophosphate-induced bronchoconstriction in patients with COPD. Clin Exp Allergy 1999; 29: 1287-1292.
19. Polosa R, Ng WH, Crimi N, et al. Release of mast-cell-derived mediators after endobronchial adenosine challenge in asthma. Am J Respir Crit Care Med 1995; 151: 624-629.
20. Brannan JD, Anderson SD, Gomes K, King GG, Chan HK, Seale JP. Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitol. Am J Respir Crit Care Med 2001; 163: 1420-1425.
21. Brannan JD, Anderson SD, Freed R, Leuppi JD, Koskela H, Chan HK. Nedocromil sodium inhibits responsiveness to inhaled mannitol in asthmatic subjects. Am J Respir Crit Care Med 2000; 161: 2096-2099.
22. Eggleston PA, Kagey-Sobotka A, Schleimer RP, Lichtenstein LM. Interaction between hyperosmolar and IgE-mediated histamine release from basophils and mast cells. Am Rev Respir Dis 1984; 130: 86-91.
23. Tomaki M, Ichinose M, Miura M, et al. Elevated substance P content in induced sputum from patients with asthma and patients with chronic bronchitis. Am J Respir Crit Care Med 1995; 151: 613-617.
24. Gong H Jr, Linn WS, Terrell SL, Anderson KR, Clark KW. Anti-inflammatory and lung function effects of montelukast in asthmatic volunteers exposed to sulfur dioxide. Chest 2001; 119: 402-408.
25. Dixon CM, Fuller RW, Barnes PJ. Effect of nedocromil sodium on sulphur dioxide induced bronchoconstriction. Thorax 1987; 42: 462-465.
26. Yang XX, Powell WS, Hojo M, Martin JG. Hyperpnea-induced bronchoconstriction is dependent on tachykinin-induced cysteinyl leukotriene synthesis. J Appl Physiol 1997; 82: 538-544.
27. Forsythe P, McGarvey LP, Heaney LG, MacMahon J, Ennis M. Sensory neuropeptides induce histamine release from bronchoalveolar lavage cells in both nonasthmatic coughers and cough variant asthmatics. Clin Exp Allergy 2000; 30: 225-232.
28. Mitsunobu F, Mifune T, Hosaki Y, et al. Enhanced production of leukotrienes by peripheral leukocytes and specific IgE antibodies in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2001; 107: 492-498.
29. Volovitz B, Welliver RC, De Castro G, Krystofik DA, Ogra PL. The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: role in obstructive airway disease. Pediatr Res 1988; 24: 504-507.
30. Kumar B, Schriever CA, Rubinstein I. Long-term montelukast therapy in patients with severe COPD (abstract). Am J Respir Crit Care Med 2002; 165: 228.